Astrana Health (ASTH) Could Be 32% Undervalued Following Its Recent Pullback
Astrana Health (ASTH) has caught investor attention after a sharp pullback, with the share price down about 9% in the past day and roughly 12% over the past month.
The latest pullback sits against a mixed backdrop for Astrana Health, with the share price return up 36% year to date but recent momentum fading over the past quarter. The 1-year total shareholder return of 15.14% contrasts with a 5-year total shareholder loss of 64.41%.
Scan the pullback in Astrana Health against other potential rebound candidates by reviewing 29 high quality undervalued stocks with strong balance sheets and solid cash generation profiles.
Astrana Health has real scale in US healthcare management, and recent share gains still leave a long trail of longer term losses. After this latest pullback, is a solid operator now being offered at a fair price or a rich one?
Most Popular Narrative: 32% Undervalued
Compared with Astrana Health's last close at $34.30, the most followed narrative framework points to a fair value of about $50.13. This frames the pullback as a valuation gap rather than just short term volatility.
Long term tailwinds from regulatory and payer shifts towards alternative payment models and value based healthcare are expanding the addressable market and favor operators with mature, risk bearing platforms like Astrana. This is cited as a potential driver for revenue and profit growth alongside rising national healthcare expenditure. The ability to deliver industry leading medical cost trend control and build trusted partnerships with payers is presented as a differentiator for Astrana relative to competitors, and a factor that may support higher contract renewal rates, lower member churn, and net margin resilience in volatile or cost constrained healthcare environments.
See why 6 investors see Astrana Health as 32% undervalued.
Result: Fair Value of $50.13 (UNDERVALUED)
Still, the Astrana Health story can change quickly if Prospect integration stumbles or if reimbursement shifts make its heavy government payer mix less profitable.
Find out about the key risks to this Astrana Health narrative.
Next Steps
Mixed signals around Astrana Health can feel confusing, so it may help to look beyond the initial price moves and evaluate both sides of the story for yourself with the 4 key rewards and 1 important warning sign.
Looking for more Astrana Health sized investment ideas?
Do not stop with Astrana Health. Use the Simply Wall St screener to scan fresh opportunities before the crowd moves and keep your watchlist working harder.
- Target potential mispricings by reviewing companies flagged in the 29 high quality undervalued stocks so you can focus on ideas where price and fundamentals may be out of sync.
- Prioritize resilience by checking the 30 resilient stocks with low risk scores and narrow in on businesses with lower risk scores that might better match your comfort level.
- Hunt for fresh prospects by scanning the 16 high quality undiscovered gems and see which under the radar stocks currently pair quality fundamentals with cleaner balance sheets.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com